TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Brief Summary: Primary objective:

* Compare the complete remission (CR) rates (i.e., the true CR, with negative immunofixation) achieved with either four courses of VD or four courses of VTD.

Secondary objectives:

* Compare the following parameters following 4 cycles of VD or VTD induction treatment:

  * CR rate+ very good partial remission (VGPR) rate
  * Overall remission rate (CR + VGPR + partial remission (PR) rate)
  * K/l light chain ratio in patients in CR.
  * Safety (quality of the sampled stem cells, extrahaematological and haematological toxicity: specially neurological toxicity, length of hospitalization).
* Compare the CR rate and the CR + VGPR rates after post-induction autologous stem cell transplantation (ASCT).


Options:
A: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
C: Arm Label: Velcade-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Dexamethasone | Arm Label: Velcade-Thalidomide-Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade-Thalidomide-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Dexamethasone; Assigned to Arm(s): Velcade-Dexamethasone | Intervention Type: DRUG; Name: Velcade-Thalidomide-Dexamethasone; Assigned to Arm(s): Velcade-Thalidomide-Dexamethasone
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan/Prednisone/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Prednisone/Velcade | Intervention Type: DRUG; Name: Melphalan/Prednisone/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Prednisone/Velcade; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)
Brief Summary: The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism \[VTE\] (i.e., Pulmonary thromboembolism \[PE\] and Deep Vein Thrombosis \[DVT\])) and safety of GSK576428 as the initial treatment in subjects with acute symptomatic DVT in an open-label design.


Options:
A: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
B: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
C: Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): N/A
D: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation of GSK576428 (Fondaparinux Sodium) in the Treatment of Acute Deep Vein Thrombosis (DVT)
Brief Summary: The primary objective of this study is to evaluate the efficacy (as measured by the rate of recurrent symptomatic Venous Thromboembolism \[VTE\] (i.e., Pulmonary thromboembolism \[PE\] and Deep Vein Thrombosis \[DVT\])) and safety of GSK576428 as the initial treatment in subjects with acute symptomatic DVT in an open-label design.


Options:
A: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
B: Arm Label: innohep®; Type: EXPERIMENTAL; Interventions: Drug: innohep® | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DRUG; Name: innohep®; Assigned to Arm(s): innohep® | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
C: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
D: Arm Label: enoxaparin and alteplase; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin ,alteplase, unfractionated heparin | Arm Label: Unfractionated heparin and alteplase; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin ,alteplase, unfractionated heparin | Intervention Type: DRUG; Name: enoxaparin ,alteplase, unfractionated heparin; Assigned to Arm(s): Unfractionated heparin and alteplase, enoxaparin and alteplase

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Double-Blinded, Randomised Controlled Trial of Doppler-Optimised Fluid Balance in Elective Colectomy Within an ERAS Protocol
Brief Summary: Perioperative fluid management has been historically dictated by outdated, contradictory concepts. Excessive or inadequate fluid administration around surgery is deleterious and hence goal-directed fluid therapy using Oesophageal Doppler-derived cardiac indices is preferable to optimize tissue perfusion. Previous studies in this area have been hampered by lack of standardization in other aspects of perioperative care and none have explored the impact of individualized fluid therapy on post-operative fatigue.The investigators proposed a study involving 80 patients having open/ laparoscopic colonic surgery to investigate the effect of Oesophageal Doppler guided fluid administration intraoperatively compared to current best practice of fluid restriction. The investigators have an optimized peri-operative care pathway established at the Manukau Surgical Centre (MSC), Middlemore Hospital. All patients will be cared for under the Enhanced Recovery After Surgery (ERAS) multimodal care plan therefore ensuring that all other aspects of care besides intraoperative fluid administration remain homogenous. Outcomes will include post-operative recovery, clinical outcomes as well as physiological data with follow-up to 30 days.


Options:
A: Intervention Type: PROCEDURE; Name: fluid management based on arterial pulse pressure variation; Assigned to Arm(s): N/A
B: Arm Label: restrictive fluid; Type: EXPERIMENTAL; Interventions: Other: restrictive and liberal fluid therapy | Arm Label: liberal fluid; Type: EXPERIMENTAL; Interventions: Other: restrictive and liberal fluid therapy | Intervention Type: OTHER; Name: restrictive and liberal fluid therapy; Assigned to Arm(s): liberal fluid, restrictive fluid
C: Arm Label: Closed-loop GDFT; Type: EXPERIMENTAL; Interventions: Device: Closed-Loop GDFT | Arm Label: Restrictive fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Fluid Therapy | Intervention Type: DEVICE; Name: Closed-Loop GDFT; Assigned to Arm(s): Closed-loop GDFT | Intervention Type: OTHER; Name: Restrictive Fluid Therapy; Assigned to Arm(s): Restrictive fluid therapy
D: Arm Label: Fluid restriction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intraoperative fluid restriction | Arm Label: Oesophageal Doppler; Type: EXPERIMENTAL; Interventions: Device: Oesophageal Doppler | Intervention Type: DEVICE; Name: Oesophageal Doppler; Assigned to Arm(s): Oesophageal Doppler | Intervention Type: PROCEDURE; Name: Intraoperative fluid restriction; Assigned to Arm(s): Fluid restriction

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Different Diets Containing Different Proportions of Carbohydrates in the Treatment of Gestational Diabetes Mellitus: A Randomized Clinical Trial
Brief Summary: There is evidence that controlling total amount of carbohydrates is a strategy for controlling glucose levels in diabetes mellitus. There is not major evidence that any given macronutrient percentage may be recommended to treat a woman with Gestational Diabetes Mellitus (GDM). In the investigators' country, insulin is the second-line treatment once medical nutrition therapy (MNT) has failed to control glucose levels during pregnancy. Insulin treatment is more expensive and not as well accepted as MNT. The investigators have designed a randomized-controlled trial to assess whether a diet with 40% total calories from carbohydrates may reduce the need of insulin treatment in women with gestational diabetes, without having unfavourable pregnancy outcomes, in comparison with a diet with 55% total calories from carbohydrates.


Options:
A: Arm Label: Low CHO; Type: EXPERIMENTAL; Interventions: Behavioral: Low CHO | Arm Label: High CHO; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High CHO diet | Intervention Type: BEHAVIORAL; Name: Low CHO; Assigned to Arm(s): Low CHO | Intervention Type: DIETARY_SUPPLEMENT; Name: High CHO diet; Assigned to Arm(s): High CHO
B: Arm Label: myo-inositol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: myo-inositol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: folic acid 400 mcg | Intervention Type: DIETARY_SUPPLEMENT; Name: myo-inositol; Assigned to Arm(s): myo-inositol | Intervention Type: OTHER; Name: folic acid 400 mcg; Assigned to Arm(s): placebo
C: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
D: Arm Label: Glyburide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glyburide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Glyburide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Brief Summary: The (Catheter Ablation Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial) CABANA Trial has the overall goal of establishing the appropriate roles for medical and ablative intervention for atrial fibrillation (AF). The CABANA Trial is designed to test the hypothesis that the treatment strategy of left atrial catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be superior to current state-of-the-art therapy with either rate control or rhythm control drugs for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients with untreated or incompletely treated AF.


Options:
A: Arm Label: PVI + Lines Ablation; Type: EXPERIMENTAL; Interventions: Procedure: PVI + Lines ablation | Arm Label: PVI Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PVI | Arm Label: PVI + CFE; Type: EXPERIMENTAL; Interventions: Procedure: PVI + CFE ablation | Intervention Type: PROCEDURE; Name: PVI + Lines ablation; Assigned to Arm(s): PVI + Lines Ablation | Intervention Type: PROCEDURE; Name: PVI; Assigned to Arm(s): PVI Ablation | Intervention Type: PROCEDURE; Name: PVI + CFE ablation; Assigned to Arm(s): PVI + CFE
B: Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy
C: Arm Label: CLOSE guided PVI and insertable cardiac monitor; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary vein isolation | Intervention Type: PROCEDURE; Name: Pulmonary vein isolation; Assigned to Arm(s): CLOSE guided PVI and insertable cardiac monitor
D: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A | Arm Label: Cohort 3; Type: N/A; Interventions: N/A | Arm Label: Cohort 4; Type: N/A; Interventions: N/A | Arm Label: Cohort 5; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Brief Summary: It is imperative to devise easy to follow, yet appropriate, guidelines for insulin use in renal-impaired patients. This will be done by comparing two regimens: 1) glargine once daily plus mealtime glulisine based on weight alone and 2) a predetermined dosing reduction algorithm with glargine/glulisine based on weight with reduction for decreased estimated GFR by MDRD as follows: \< 30 ml/min/1.73m2 or on dialysis reduce dose by 50% from weight based calculation.


Options:
A: Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Saxagliptin 2.5 mg QAM (A); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Saxagliptin 2.5 mg titrated to 5 mg QAM (B); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Saxagliptin 5 mg QAM (C); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Saxagliptin 5 mg QPM (D); Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: metformin | Arm Label: Placebo (E); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg QAM (A) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 2.5 mg titrated to 5 mg QAM (B) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg QAM (C) | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin 5 mg QPM (D) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (E) | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Placebo (E), Saxagliptin 2.5 mg QAM (A), Saxagliptin 2.5 mg titrated to 5 mg QAM (B), Saxagliptin 5 mg QAM (C), Saxagliptin 5 mg QPM (D)
C: Arm Label: Saxa; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: Placebo; Type: NO_INTERVENTION; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 0.5 units/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.5 units/kg daily insulin | Arm Label: 0.25 units/kg; Type: EXPERIMENTAL; Interventions: Drug: 0.25 units/kg daily insulin | Intervention Type: DRUG; Name: 0.5 units/kg daily insulin; Assigned to Arm(s): 0.5 units/kg | Intervention Type: DRUG; Name: 0.25 units/kg daily insulin; Assigned to Arm(s): 0.25 units/kg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Brief Summary: To find out if vitamin D supplementing can lead to an improvement in immunological status in HIV-infected children as part of routine clinical care


Options:
A: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins - vitamins B complex, C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Multivitamins - vitamins B complex, C and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin D | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol (vitamin D) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol (vitamin D); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Brief Summary: To find out if vitamin D supplementing can lead to an improvement in immunological status in HIV-infected children as part of routine clinical care


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamins | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins; Assigned to Arm(s): Multivitamins | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 7000IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): 7000IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cholecalciferol plus calcium carbonate | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol plus calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol plus calcium carbonate; Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementation and CD4 Count in HIV-Infected Children
Brief Summary: To find out if vitamin D supplementing can lead to an improvement in immunological status in HIV-infected children as part of routine clinical care


Options:
A: Arm Label: Vitamin D (10 microgram/day); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Vitamin D (20 microgram/day); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Arm Label: Placebo control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Vitamin D (10 microgram/day), Vitamin D (20 microgram/day)
B: Arm Label: RUTF with Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D, Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Arm Label: RUTF with Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Ready to Use Therapeutic Food (RUTF) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): RUTF with Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Ready to Use Therapeutic Food (RUTF); Assigned to Arm(s): RUTF with Placebo, RUTF with Vitamin D
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: 400 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 4000 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 400 IU vitamin D, 4000 IU vitamin D

Answer: C